Market News
- Sage to cut one-third of workforce, streamline drug pipelineby Delilah Alvarado (BioPharma Dive – Latest News) on October 17, 2024
The restructuring, which follows clinical setbacks in Alzheimer’s, Parkinson’s and tremor, will also involve the departure of five senior executives.
- After rejections, AbbVie secures approval for Parkinson’s drugby Jacob Bell (BioPharma Dive – Latest News) on October 17, 2024
Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired through its Cerevel buyout.
- Sanofi, expanding in radiopharma, strikes a joint venture dealby Ned Pagliarulo (BioPharma Dive – Latest News) on October 17, 2024
The French drugmaker will invest 300 million euros into a new entity that will develop lead isotope-based therapies for cancer under the Orano Med brand.
- Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europeby Kristin Jensen (BioPharma Dive – Latest News) on October 17, 2024
The deal offers Lexicon a cash infusion of $25 million as the company tries to broaden use of the heart failure and diabetes medication.
- FDA Approves AbbVie’s Vyalev for Advanced Parkinson Diseaseby OncLive articles on October 17, 2024
Vyalev is the first and only FDA-approved subcutaneous 24-hour infusion of a levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson disease.
- Fresenius Kabi and Cellular Origins agree CGT manufacture automationby gullapalli (Pharmaceutical Technology) on October 17, 2024
Fresenius Kabi and Cellular Origins have announced a partnership to advance cell and gene therapy (CGT) by automating manufacturing.
- Health Canada approves Acadia’s DAYBUE for Rett syndromeby gullapalli (Pharmaceutical Technology) on October 17, 2024
Acadia Pharmaceuticals has received marketing authorisation from Health Canada for DAYBUE (trofinetide) to treat Rett syndrome.
- ISTH Issues Survey for World Thrombosis Dayby OncLive articles on October 17, 2024
The organization hopes to collect data to provide better education around Thrombosis.
- Navigating Social Media Regulatory and Ethical Standardsby OncLive articles on October 17, 2024
In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member explains how pharmaceutical companies can effectively navigate the evolving regulatory landscape and […]
- Managing Data from Clinical Trials: Q&A with Rust Felixby OncLive articles on October 17, 2024
Slope’s CEO and co-founder discusses technological advances that are solving problems with data collection and sorting from clinical trials.
- Pharma Pulse 10/17/24: Analyzing Drug Pricing and Reimbursement Data, Pharmacogenomics in Optimizing Opioid Therapy & moreby OncLive articles on October 17, 2024
The latest news for pharma industry insiders.
- Incyte Adds Dr. Pimple Popper to Atopic Dermatitis Initiativeby OncLive articles on October 17, 2024
Dr. Sandra Lee is joining the educational program, which originally launched last year.
- Findings from the NIAGRA Trial in Bladder Cancer and Mechanisms of Resistanceby OncLive articles on October 17, 2024
Shubh Goel, head, immune-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses findings from the NIAGRA trial regarding bladder cancer
- Lexicon partners Viatris for global expansion of sotagliflozinby gullapalli (Pharmaceutical Technology) on October 17, 2024
Lexicon Pharmaceuticals has entered a licensing agreement with Viatris to commercialise sotagliflozin outside the US and Europe.
- J&J trims neuroscience pipeline – seltorexant in Alzheimer’s disease dropped by Robert Barrie (Pharmaceutical Technology) on October 16, 2024
J&J has cut two Phase II programmes and one Phase I asset in its neuroscience portfolio.
- Nipocalimab Demonstrates Sustained Disease Control in Adolescents with Generalized Myasthenia Gravisby OncLive articles on October 16, 2024
Results from the Phase II/III Vibrance-MG study found that patients with generalized myasthenia gravis who were treated with nipocalimab plus standard-of-care achieved sustained disease control.
- Eli Lilly will ‘build new way of doing science’ in UK amid £297m pledge to governmentby Jenna Philpott (Pharmaceutical Technology) on October 16, 2024
Lilly’s senior VP of information and R&D IT Ramesh Durvasula said Lilly will use AI and tech to transform the company.
- Novocure wins FDA approval for electric field device in lung cancerby Jonathan Gardner (BioPharma Dive – Latest News) on October 16, 2024
Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.
- Wave sees RNA editing validation in early trial resultsby Ben Fidler and Ned Pagliarulo (BioPharma Dive – Latest News) on October 16, 2024
The data provide the first clinical evidence of RNA editing, a burgeoning field that’s drawn interest from biotechs and pharmaceutical companies alike.
- FDA puts Novavax flu vaccine trials on holdby Delilah Alvarado (BioPharma Dive – Latest News) on October 16, 2024
The hold, which was made in response to a serious adverse event report, could impact the company’s plans to start a Phase 3 trial of a combination shot for COVID-19 and influenza.